Peritoneoscopy for surgeons.

T E Udwadia

Home/Archive/PubMed

PubMed · 2942093

Peritoneoscopy for surgeons.

T E Udwadia

View original source ↗Export metadata ↓

Abstract

Peritoneoscopy is an invasive procedure. With attention to detail and a degree of dexterity which is inherent to surgery the procedure has been found safe in over 2,500 cases. Peritoneoscopy must always be a sequel to careful clinical examination. The greatest advantage of peritoneoscopy over all other diagnostic modalities is that peritoneoscopic diagnosis is a final histological diagnosis and has no element of shadow, image or conjecture. Peritoneoscopy has its greatest value in the diagnosis of liver pathology, in ascites, jaundice, malignancy and tuberculosis especially if non-invasive scanning techniques are not available. When used with discretion, it has some value in the management of the acute abdomen. Surgeons will be gratified to find the extent to which the peritoneoscope can help arrive at an early histological diagnosis, plan surgery, reduce morbidity by avoiding unnecessary surgery and shorten hospitalisation.

Explore related subjects

Ascites Biopsy Hepatomegaly Humans Jaundice Laparoscopy Liver Diseases Peritonitis, Tuberculous Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

T E Udwadia. 1986. Peritoneoscopy for surgeons.. https://pubmed.ncbi.nlm.nih.gov/2942093/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Immunotherapy of malignant ascites with trifunctional antibodies.

A new class of intact bispecific antibodies shows unmet effector qualities by activation of not only T cells but also simultaneous activation of Fcgamma receptor type I/III+ cells (macrophages, NK-cells and DC). These trifunctional antibodies (trAb) lead to efficient specific killing of targeted tumor cells without any pre- or co-stimulation. This concept was investigated in vivo in patients with malignant ascites in a clinical situation that allowed monitoring of tumor cell elimination and correlation with clinical effects. In a prospective study, 8 patients with malignant ascites due to peritoneal carcinomatosis were treated with intraperitoneal application of trAb, which bound either the EpCAM- or Her2/neu-antigen on tumor cells. Treatment consisted of 4-6 applications within 9-23 days with a total amount of 145-940 microg. Seven of eight patients required no further paracentesis during follow-up or until death with a mean paracentesis-free interval of 38 weeks (median = 21.5, range = 4-136). Tumor cell monitoring showed a complete elimination of tumor cells in ascites already at total doses as low as 40-140 microg. Clinical response with disappearance of ascites accumulation was seen in all patients, which was correlated with elimination of tumor cells (p = 0.0014). Severe adverse events were not observed. Clinically relevant side effects were fever, moderate abdominal pain and skin reactions. Intraperitoneal immunotherapy with trAb showed convincing efficacy in patients with malignant ascites. This treatment offers new therapeutic options for patients with peritoneal carcinomatosis.

Ascites↗

PubMed2005

Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.

Interactions between cancer cells and the surrounding medium are not fully understood. In this study, we demonstrate that ascites induces selective changes in the expression of integrins and urokinase plasminogen activator/urokinase plasminogen activator receptor (uPA/uPAR) in ovarian cancer cells. We hypothesise that this change of integrin and uPA/uPAR expression triggers signalling pathways responsible for modulating phenotype-dependent functional changes in ovarian cancer cells. Human ovarian surface epithelial (HOSE) cell lines and epithelial ovarian cancer cell lines were treated with ascites for 48 h. Ascites induced upregulation of alpha6 integrin, without any change in the expression of alphav, beta1 and beta4 integrin subunits. Out of the four ovarian cancer cell lines studied, ascites induced enhancement in the expression of uPA/uPAR in the more invasive OVCA 433 and HEY cell lines without any change in the noninvasive OVHS1 and moderately invasive PEO.36 cell lines. On the other hand, no change in the expression of alpha6 integrin or uPAR, in response to ascites, was observed in HOSE cells. In response to ascites, enhancement in proliferation and in adhesion was observed in all four ovarian cancer cell lines studied. In contrast, no significant increase in proliferation or adhesion by ascites was observed in HOSE cells. Ascites-induced expression of uPA/uPAR correlated with the increased invasiveness of HEY and OVCA 433 cell lines but was not seen in OVHS1, PEO.36 and HOSE cell lines. Upregulation of alpha6 integrin and uPA/uPAR correlated with the activation of Ras and downstream Erk pathways. Ascites-induced activation of Ras and downstream Erk can be inhibited by using inhibitory antibodies against alpha6 and beta1 integrin and uPAR, consistent with the inhibition of proliferation, adhesion and invasive functions of ovarian cancer cell lines. Based on these findings, we conclude that ascites can induce selective upregulation of integrin and uPA/uPAR in ovarian cancer cells and these changes may modulate the functions of ovarian carcinomas.

Ascites↗

PubMed2005

Multiple myeloma presenting initially as a solitary pleural effusion later complicated by malignant plasmacytic ascites.

A pleural effusion is a rare presenting feature of multiple myeloma and can be a complication of myelomatous ascites as well. An additional unique feature of our case includes the finding of a normal bone marrow at the time of presentation despite the aggressive course of the disease. To the best of our knowledge after an extensive medical literature review, this case is the first one of multiple myeloma presenting with a plasmacytic pleural effusion, a negative bone marrow, and a late complication of plasmacytic ascites. Involvement of serous cavities in myeloma carries a poor prognosis, and there is currently no standard effective treatment regimen.

Ascites↗